Literature DB >> 10434011

Topiramate reduces neuronal injury after experimental status epilepticus.

M Niebauer1, M Gruenthal.   

Abstract

Prolonged seizures are associated with injury to vulnerable neurons, particularly in the hippocampus. Identification of compounds that attenuate injury after prolonged seizures could be of value in the management of refractory status epilepticus. We hypothesized that topiramate, an anticonvulsant with multiple mechanisms of action, would attenuate hippocampal neuronal injury when given after experimental status epilepticus. Limbic status epilepticus was induced in adult male Wistar rats for 140 min by unilateral hippocampal electrical stimulation. Rats then received intraperitoneal injections of either vehicle (n=6) or topiramate at 20 mg/kg (n=6), 40 mg/kg (n=7) or 80 mg/kg (n=7). Three days later, hippocampal sections were processed for neuronal degeneration using a silver impregnation stain. Seizure-induced damage was assessed by measuring the density of silver staining in hippocampal regions CA1, CA3 and dentate hilus. Administration of topiramate at each dose was associated with a significant reduction in staining density bilaterally in area CA1 and the dentate hilus. Reduction in staining density in area CA3 was seen contralateral to the side of stimulation at the two higher topiramate doses only. The results indicate that administration of topiramate after experimental status epilepticus can attenuate seizure-induced hippocampal neuronal injury. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10434011     DOI: 10.1016/s0006-8993(99)01615-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

Review 1.  Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.

Authors:  Wolfgang Löscher; Claudia Brandt
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients.

Authors:  Bankole A Johnson; Nassima Ait-Daoud
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

4.  Treatment of pediatric refractory status epilepticus with topiramate.

Authors:  Başak Nur Akyildiz; Sefer Kumandaş
Journal:  Childs Nerv Syst       Date:  2011-03-26       Impact factor: 1.475

5.  Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study.

Authors:  Annalena Hottinger; Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2012-09-01       Impact factor: 5.749

Review 6.  The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.

Authors:  Rafal M Kaminski; Michael A Rogawski; Henrik Klitgaard
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

7.  Topiramate: Effects on cognition in patients with epilepsy, migraine headache and obesity.

Authors:  Barbara R Sommer; Erica L Mitchell; Tonita E Wroolie
Journal:  Ther Adv Neurol Disord       Date:  2013-07       Impact factor: 6.570

Review 8.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

Review 9.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

10.  Topiramate in the treatment of partial and generalized epilepsy.

Authors:  Edward Faught
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.